Endothelin and endothelin receptors in the renal and cardiovascular systems  by Vignon-Zellweger, Nicolas et al.
Life Sciences 91 (2012) 490–500
Contents lists available at SciVerse ScienceDirect
Life SciencesReviewj ourna l homepage: www.e lsev ie r .com/ locate / l i fesc ieEndothelin and endothelin receptors in the renal
and cardiovascular systemsNicolas Vignon-Zellweger a, Susi Heiden a, Takashi Miyauchi b, Noriaki Emoto a,c,⁎
a Kobe Pharmaceutical University, Clinical Pharmacy, Japan
b Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Japan
c Kobe University Graduate School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine, Japan⁎ Corresponding author at: Division of Cardiovascular
Kobe 650–0017, Japan. Tel.: +81 78 382 5846; fax: +8
E-mail address: emoto@med.kobe-u.ac.jp (N. Emoto
0024-3205 © 2012 Elsevier Inc.
http://dx.doi.org/10.1016/j.lfs.2012.03.026
Open access under CC Ba b s t r a c ta r t i c l e i n f oArticle history:
Received 19 December 2011
Accepted 16 March 2012
Keywords:
Endothelin-1
Endothelin receptor
Molecular biology
Heart
Vasculature
KidneyEndothelin-1 (ET-1) is amultifunctional hormonewhich regulates the physiology of the cardiovascular and renal
systems. ET-1 modulates cardiac contractility, systemic and renal vascular resistance, salt and water renal reab-
sorption, and glomerular function. ET-1 is responsible for a variety of cellular events: contraction, proliferation,
apoptosis, etc. These effects take place after the activation of the two endothelin receptors ETA and ETB, which
are present – among others – on cardiomyocytes, ﬁbroblasts, smooth muscle and endothelial cells, glomerular
and tubular cells of the kidney. The complex and numerous intracellular pathways, which can be contradictory
in term of functional response depending on the receptor type, cell type and physiological situation, are de-
scribed in this review. Many diseases share an enhanced ET-1 expression as part of the pathophysiology.
However, the use of endothelin blockers is currently restricted to pulmonary arterial hypertension, andmore re-
cently to digital ulcer. The complexity of the endothelin systemdoes not facilitate the translation of themolecular
knowledge to clinical applications. Endothelin antagonists can prevent disease development but secondary un-
desirable effects limit their usage. Nevertheless, the increasing understanding of the effects of ET-1 on the cardiac
and renal physiology maintains the endothelin system as a promising therapeutic target.
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Generation of endothelin
Endothelins comprise a family of three peptides, ET‐1, ET‐2 and ET‐3
derived from three distinct genes. The expression of ET‐2 and ET‐3 differs
fromET‐1 relatively to the tissue type (Matsumoto et al., 1989; Saida et al.,
2002). ET‐1 is the predominant isoform in vivo. The human and mouse
EDN1 genes code for a biologically inactive 212 and 202 amino acids
(aa) preproendothelin‐1 (PPET1), respectively. The promoter of the
EDN1 gene presents numerous regulatory elements and its transcription
is therefore regulated by many hormonal and environmental stimuli
(tumor necrosis factor‐alpha, interleukins, insulin, norepinephrine, angio-
tensin II, thrombin, natriuretic peptides, nitric oxide (NO), prostacyclin)
which are extensively reviewed (Stow et al., 2011). PPET1 is cleaved
into the 38 aa big endothelin‐1 (big ET‐1) by speciﬁc furin‐like proteases
(Denault et al., 1995). The active 21 aa peptide ET‐1 is produced from big
ET‐1mainly through the proteolytic action of three endothelin converting
enzymes (ECE-1, ECE-2, ECE-3) (Xu et al., 1994; Emoto and Yanagisawa,
1995; Hasegawa et al., 1998), which exist under different splice variants
(Emoto et al., 1999; Ikeda et al., 2002), but ET-1 can be produced also
by other enzymes (Orleans-Juste et al., 2003). Human and mouse ET‐1
amino acid sequences are identical. Alternatively, chymases can cleave
big ET‐1 into a 31 aa active peptide (ET‐11–31) (Nagata et al., 2000).
Importantly, ECEs can have proteolytic actions on other peptides
(Mzhavia et al., 2003). Big ET‐1 has no biological function apart from
the protection from proteolysis cleavage of endothelin and binds to the
endothelin receptors but with a much lower afﬁnity (Hemsen et al.,
1991). ET‐1, for its part, exhibits low plasma concentration because of
thequasi irreversible feature of ET-1binding to its receptors and the clear-
ing operated by them after binding (Johnstrom et al., 2005). ET-1 acts
therefore as a para‐ and autocrine hormone.Endothelin receptors
Shortly after the discovery of ET‐1, two types of seven transmem-
brane G protein‐coupled receptors were cloned called endothelin re-
ceptor A (ETA) (Arai et al., 1990) and ETB (Sakurai et al., 1990). The
afﬁnity of the ETA receptor for ET-3 is less than its afﬁnity for ET-1 and
ET-2, while the ETB receptor binds the three endothelins with the
same afﬁnity. No speciﬁc agonist for the ETA receptor and only two
ETB receptor agonists, sarafotoxin 6c and IRL1620, are actually available
(Watts, 2010). However, the study of each receptor's role has been facil-
itated with the development of several selective antagonists for both
ETA receptors (e.g. atrasentan) (Jae et al., 2001) and ETB receptors (e.g.
BQ‐788) (Ishikawa et al., 1994) and dual antagonists, like bosentan
(Clozel et al., 1994) or more recently developed macitentan (Iglarz
et al., 2008). ET‐1 has a similar afﬁnity for both receptors (Arai et al.,
1990; Sakurai et al., 1990). The intracellular pathways installed after
ET‐1-induced ETA and ETB receptors activation involve the Gq, Gs and
Gi small G proteins leading to stimulation of phospholipase C (PLC).
The consecutive production of inositol triphosphate (IP3) and diacylgly-
cerol (DAG) increases the concentration of intracellular calcium (Ca2+).
Ca2+ is recruited from the reticulum by activation of the inositol tri-
phosphate (IP3) receptor and external Ca2+ inﬂux is increased by open-
ing of the Ca2+ channels on the cellular membrane (Simonson and
Dunn, 1990). ETA and ETB receptors can have synergetic or opposing ef-
fects depending on cell type, tissue type or physiological situation. TheETA receptor shows an atypical long-lasting agonist-induced effect
because ET-1 dissociates particularly slowly from its receptors.
Based on a two-state two-site model, it has been proposed that ET-
1 and ETA receptor antagonists bind to distinct sites and antagonists
therefore prevent the binding of ET-1 but may reduce only partly the
actions of already bound ET-1 (De Mey et al., 2011).
After activation, the ETB receptor is internalized and targeted to the
lysosome (Bremnes et al., 2000). ETB receptor selective (Strachan et al.,
1999), non-selective (Iglarz et al., 2008) and in a much lesser extent se-
lective ETA receptor antagonists (Opgenorth et al., 2000) elevate the
serum level of ET-1. Together these data reveal the predominant role
of the ETB receptors for the clearance of circulating ET-1, which occurs
mainly in the lungs and the kidneys (Johnstrom et al., 2005).
The presence of homo- and heterodimers of the endothelin recep-
tors has been recently observed in vitro and possibly counts for the
complexity of ET-1 responses. The types of dimers (ETA/ETA, ETA/ETB,
or ETB/ETB) are characterized by different binding density (Evans and
Walker, 2008). Moreover, the functional response is different whether
homo- or heterodimers are formed: the binding of ET-1 to homodimers
induces a transient elevation in Ca2+ concentration, while the response
mediated by heterodimers lasts for several minutes (Evans andWalker,
2008). In pulmonary arteries of rats, Sauvageau et al. (2009) could dem-
onstrate by co-immunoprecipitation a heterodimerization of the two
endothelin receptors. Furthermore, endothelin receptors could possibly
form dimers with other receptors: Zeng et al. proposed that the loss of
the dopamine receptor function in renal tubule of hypertensive rats is
due to impaired binding to the ETB receptor (Zeng et al., 2008a). The
functional relevance of these observations and particularly how phar-
macological observations could be explained by the formation of dimers
was recently discussed elsewhere (Watts, 2010). Finally, a molecule
could represent an alternative target of ET-1: a dual ET-1/angiotensin
II receptor called DEAR (Ruiz-Opazo et al., 1998).ET-1 in the vasculature
Effects of ET-1 on vascular tone
Historically, ET-1 is a hormone responsible for the maintenance
of the vascular tone. ETA receptors are expressed on vascular smooth
muscle cells and ETB receptors on both endothelial and vascular
smooth muscle cells (Fig. 1). 80% of ET-1 produced by endothelial
cells (EC) diffuse through the basal side in the vascular wall and
bind to both ETA and ETB receptors on smooth muscle cells, which
leads to a vasoconstriction of the vessels (Wagner et al., 1992)
(Fig. 1). Importantly, each vascular bed presents a different distribu-
tion of the receptors, which modulates the response to ET-1 (Calo
et al., 1996). The binding of ET-1 to the ETA receptor activates the
PLC. The increased production of IP3 promotes the mobilization of
the reticular and extracellular Ca2+ (Bkaily et al., 1995; Curtis and
Scholﬁeld, 2001). The Ca2+ entry provokes a cascade of ion channel
opening which tends to depolarize the smooth muscle cells. The
opening of chloride channels and the inhibition of potassium chan-
nels consequently to the increase of intracellular Ca2+ participate
also to the ET-1 response. The activity of the Na+/H+ exchangers
plays a role in the ET-1-induced elevation of intracellular Ca2+ too
(Motte et al., 2006). In contrast, ET-1 which diffuses in the plasma
activates ETB receptors on endothelial cells, which promotes endo-
thelial nitric oxide synthase (eNOS) derived NO release through a
Fig. 1. ET-1 expression, regulation and actions inside the vesselwall. NO=nitric oxide, eNOS=endothelial nitric oxide synthase, PLC=phospholipase C, sGC= soluble guanylyl cyclase,
IP3 = inositoltriphosphate, cGMP = cyclic guanoside monophosphate, TNFα= tumor necrotic factor alpha, ANP = atrial natriuretic peptide, BNP = brain natriuretic peptide.
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way. NO, in turn, reduces the concentration of intracellular Ca2+
with concomitant vasodilation (Tsukahara et al., 1994) (Fig. 1).
The ETB-induced vasodilation involves also cyclooxygenases, prostacy-
clins and voltage-dependent potassium channels (Tirapelli et al., 2005).
In rats, infusion of exogenous ET-1 leads to a short vasodilation
and decrease in blood pressure followed by a strong and lasting ele-
vation of blood pressure (Yanagisawa et al., 1988). The initial vasodi-
lation was later attributed speciﬁcally to the ETB receptor (McMurdo
et al., 1994), while the contractile effect is the result of the activation
of both receptors (Pernow and Modin, 1993). Selective blockade of
ETA receptors enhances NO-mediated vasodilation (Verhaar et al.,
1998; Prié et al., 1998; Barton et al., 1998) that can be acutely blocked
by ETB receptor antagonists (Verhaar et al., 1998) whereas blockade
of ETB receptors induces vasoconstriction (Pernow and Modin,
1993; Matsuura et al., 1997). Genetic deﬁciency of ET-1 slightly ele-
vates blood pressure in mice (Kurihara et al., 1994), this hypertension
is probably due to the renal effect of ET-1 discussed later. Systemic
genetic overexpression of ET-1 or limited to the vasculature induces
vascular dysfunction but does not impact blood pressure (Hocher
et al., 1997; Amiri et al., 2004). A compensationof the functional antag-
onist of ET-1 nitric oxide may be responsible for the lack of hyperten-
sion in these mice (Hocher et al., 2004). However, mice in which ET-1
is deleted speciﬁcally in vascular EC are moderately hypotensive con-
ﬁrming the importance of ET-1 in vascular tone (Kisanuki et al., 2010).
Other effects of ET-1 on the vasculature: growth and inﬂammation
Beside its major role on vascular tone, ET‐1 possesses mitogenic ef-
fects on vascular smooth muscle cells. Proto-ocongenes are activated
subsequently to the mitogen activated protein kinases (MAPK) cas-
cades, under the control of ET-1 (Clerk et al., 2002). ET-1 is also respon-
sible for ﬁbroblasts proliferation (MacNulty et al., 1990) and induces
cytokine production through the ETA receptor on macrophages
(Ruetten and Thiemermann, 1997). In mice, genetic overexpression ofET-1 in EC enhances oxidative stress due to increase NADPH oxidase ac-
tivity, promotes vascular hypertrophy and induces a local inﬂammation
characterized bymacrophage inﬁltration (Amiri et al., 2008). After carot-
id ischemia, ET-1 from EC origin is responsible for inﬂammation through
the elevation of adhesion molecule expression and for vascular smooth
muscle proliferation leading to neointima formation (Anggrahini et al.,
2009). These effects are associatedparticularlywithpulmonary hyperten-
sion and atherosclerosis.
ET-1 in the heart
Inotropic effects of ET-1
Both ETA and ETB receptors are expressed throughout the cardiac
muscle, including the coronary vasculature. Cardiomyocytes express
predominantly ETA receptors while both receptors are equally repre-
sented on cardioﬁbroblasts (Fareh et al., 1996). Activation of the ETA
receptor results in increased contractility (MacCarthy et al., 2000).
In consequence, overexpression of ET-1 in mice reduces time of dia-
stolic relaxation (Vignon-Zellweger et al., 2011). The molecular
mechanisms mediating this positive inotropic effect include an in-
crease in intracellular Ca2+ concentration (Talukder et al., 2001).
The activation of ETA receptors elevates the production of IP3 by the
PLC, which results in reticular Ca2+ recruitment. The L-type Ca2+
channels, which are responsible for the main depolarizing current,
provide the response to ET-1 after activation of ETA receptors, protein
kinase C (PKC) and the Ca2+/calmodulin kinase (Komukai et al.,
2010). ET-1 induces an alkalization of the myocytes through an acti-
vation of the Na+/H+ exchanger by a mechanism involving the
DAG-stimulated PKC and tyrosine kinases. This alkalization increases
the sensitivity of the myoﬁlament to Ca2+ (Endoh, 2006). The activity
of the Na+/H+ exchanger induces the activation of the Na+/Ca2+ ex-
changers, which further increases intracellular Ca2+. Superoxide pro-
duced by the NADPH oxydase activated by ET-1 may also participate
to the activation of Ca2+ channels (Zeng et al., 2008b). Endogenous
Fig. 2. Actions of ET-1 on water and salt handling in the renal tubules. AQP2 = aquaporin 2, AC = adenylate cyclase, PKC = protein kinase C, MAPK = mitogen-activated protein
kinases, eNOS: endothelial nitric oxide synthase, ENaC = sodium channel, PGE = prostaglandin.
493N. Vignon-Zellweger et al. / Life Sciences 91 (2012) 490–500ET-1 is also responsible for the positive inotropic effect of angiotensin
II via the production of reactive oxygen species (Cingolani et al.,
2006). In themouse heart, endogenous ET-1may increase and decrease
contractility via ETA and ETB receptors, respectively (Piuhola et al.,
2003a). Moreover, the actual knowledge suggests that the effects of en-
dogenous ET-1may differ depending on the pathological situations. ET-
1 has been showed to induce a negative inotropic effect reportedly after
activation of ETB receptors and consecutive activation of Na+/Ca2+ ex-
changers (Nishimaru et al., 2007). This may be the case in the failing
heart, where Na+/Ca2+ exchanger are overexpressed (Namekata
et al., 2008). In order to investigate the local effect of ET-1 on the cardiac
muscle independently from systemic effects on the vasculature, intra-
coronary injection of the ETA receptor antagonist BQ-123 has been
used. This experimental setting revealed that, in healthy humans, the
positive inotropic effect of ET-1 is rather modest and that in patients
with heart failure, blocking endogenous ET-1 actions on ETA receptors
tends to increase contractility (MacCarthy et al., 2000). In the normal
isolated rat heart, bosentan has no effect on contractility but decreases
systolic function in hypertrophic hearts (Piuhola et al., 2003b).
Hypertrophic and proﬁbrotic effects of ET-1
ET-1 promotes cardiac hypertrophy via several pathways. The
binding of ET-1 to ETA receptors induces the dissociation of small Gproteins, the activation of PLC and production of IP3 and DAG in myo-
cytes (Shubeita et al., 1990). In response to ET-1, mainly PKCδ and
PKCε are activated by DAG. PKC provokes the exchange of GDP to
GTP from the small G protein Ras, which can thus activate the protein
kinase cascade Raf-MKK1/2-ERK1/2 (Bogoyevitch et al., 1994). Final-
ly, ERK1/2 promotes the transcription of the genes coding for early re-
sponse transcription factor, which causes hypertrophy (Marshall
et al., 2010). Ion exchangers mediate also the hypertrophic response
of the heart to ET-1 (Dulce et al., 2006). The vascular endothelial
growth factor and tumor growth factor-beta pathways participate in
the hypertrophic response of myocytes to endothelin-1 treatment
(Shimojo et al., 2006, 2007). ET-1 induces thus myocardial hypertro-
phy and is overexpressed in case of heart failure. The long-term
blockade of ET-1 actions improves the survival rate in a rat model
for chronic heart failure (Sakai et al., 1996). We reported that these
beneﬁcial effects include the prevention of the alteration in the ex-
pression of the genes coding for the angiotensin-converting enzyme,
angiotensin II type 1 receptor among others (Sakai et al., 2000).
Using cultured cardiomyocytes and rats with aortic banding-
induced cardiac hypertrophy, we have shown that the transcription
of the ET-1 gene is regulated by PPARα, the phorbol-ester-sensitive
c-fos and c-jun complexes, the nuclear factor-1, AP-1, and GATA pro-
teins (Irukayama-Tomobe et al., 2004). Additionally, ﬁbroblasts ex-
press ET-1, which induces their growth via the ETA receptor. This
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triuretic peptides, respectively (Fujisaki et al., 1995). Wehave showed
that ET-1 from EC may be responsible for the induction of ﬁbroblasts
formation in the failing diabetic heart (Widyantoro et al., 2010). Finally,
genetic ECE-1 inhibition in mice reduces doxorubicin-induced cardio-
myopathy by a prevention of mitochondrial dysfunction (Miyagawa
et al., 2010).Cardio-protective properties of ET-1
On the other hand, some animal models revealed a rather neutral
role for cardiac ET-1. For instance, mice lacking the ETA receptor in
cardiomyocytes develop normally and do not present a modiﬁed car-
diac hypertrophic response to stress (Kedzierski et al., 2003). This in
line with observations from our group, which indicate that ET-1
from EC is not required for afterload-induced cardiac hypertrophy in
mice (Heiden et al., unpublished).
Importantly, myocardial ET-1 depicts beneﬁcial effects depending on
the physiological situation. In the myocardium, ET-1 may prevent exces-
sive apoptosis after cardiac overload induced by aortic banding (Zhao
et al., 2006). Signaling of the antiapoptotic effects of ET-1 involves calci-
neurin, the mitochondrial function and the classical MEK1/2-ERK1/2
and PI3 kinase pathways (Iwai-Kanai and Hasegawa, 2004). We reported
that ET-1 prevents the early phase of doxorubicin-induced cytotoxicity
via the upregulation of the antioxidantmanganese superoxide dismutase
through the ETA receptor in cultured cardiomyocytes (Suzuki and
Miyauchi, 2001). Preconditioning infusion of ET-1 can reduce infarct
size in rats subjected to ischaemia/reperfusion (Gourine et al., 2005).
The transgenic expression of ET-1 in mice lacking a functional gene for
eNOS restores diastolic function presumably through modulation of oxi-
dative stress and a change of metabolic substrate (Vignon-Zellweger
et al., 2011). In line with this, the enhanced glycolysis in the failing
heart, which is a beneﬁcial compensatory mechanism, is accompanied
by a hypoxia-inducible factor-1αdependant elevation of ET-1 expression
(Kakinuma et al., 2001).Clinical use of endothelin antagonists in heart failure
Taken together, cardiac ET-1 induces numerous cellular responses
which may be contradictory depending on the situations. On the light
of this, one may guess the reasons why treatment with either bosen-
tan, tezosentan, enrasentan or darusentan did not improve outcome
in chronic heart failure patients (Mylona and Cleland, 1999;
O'Connor et al., 2003; Anand et al., 2004; Battistini et al., 2006). In
these clinical studies, the patients were receiving already recom-
mended doses of classical drugs (angiotensin-converting-enzyme in-
hibitors, angiotensin receptor antagonists, β-blockers, aldosterone
antagonist, or spironolactone). These treatments may have masked
the effects of endothelin antagonists. Whether treatment with
endothelin receptor antagonists alone may present a favorable effect
is currently questionable. Nevertheless, heart failure patients receiv-
ing these various endothelin antagonists suffered from an even
higher number of adverse events. These side effects could have possi-
bly been prevented by the use of lower doses but this question has al-
ready been addressed for bosentan unsuccessfully (Kalra et al., 2002).
In most of these studies, the patients were severely affected (NYHA
classes III–IV) and endothelin antagonists may be effective in the
early phases of the pathology only. Moreover, this category of pa-
tients is very sensitive to drugs having strong hemodynamic effects
like endothelin antagonists. Finally, the cardio-protective properties
of ET-1 discussed earlier might account for the results of these stud-
ies. In spite of these disappointing clinical results, the question
whether chronic blockade of the endothelin system might be beneﬁ-
cial in particular cardiac conditions remains open.ET-1 in the kidney
ET-1 in the renal vasculature
Similarly to the rest of the vasculature, ETA receptors are present
on both smooth muscle cells and EC while ETB receptor expression
is restricted to EC in the kidney (Wendel et al., 2006) (Fig. 3). Physi-
ological doses of ET-1 contribute to renal hemodynamics and regulate
thereby glomerular pressure (Qiu et al., 1995).
Whether ET-1 contracts predominantly afferent or efferent arteri-
oles and thereby controls glomerular ﬁltration rate (GFR) remains
disputed. Seminal studies showed that ET-1 sensitivity is relatively
greater in afferent than in efferent arterioles and ET-1 thus may re-
duce GFR (Edwards et al., 1990). In isolated cortical arterioles from
ETB receptor deﬁcient mice, the ETA receptor participates to afferent
and efferent arterioles contraction whereas ETB receptor activation
in wild type (WT) mice has no effect in cortical afferent arterioles
but induces NO-mediated vasodilatation in efferent arterioles
(Schildroth et al., 2011). ET-1 constricts therefore preferentially affer-
ent arterioles and diminishes GFR. Consistently, infusion of ET-1
slightly reduces GFR in humans too (Vuurmans et al., 2004). Denton
et al. showed that infusion of ET-1 constricts both afferent and effer-
ent arterioles without modifying GFR but increasing ﬁltration frac-
tion, which may suggest an increased glomerular pressure (Denton
et al., 2004). ET-1 effect on the resistance of efferent vessels might
be stronger because of their smaller diameter. Moreover, speciﬁc
ETA receptor blockade elevates renal plasma ﬂow, reduces ﬁltration
fraction, possibly reduces glomerular pressure but does not affect
GFR in patients with chronic kidney disease (Goddard et al., 2004;
Dhaun et al., 2007). Again, this points to a preferential constrictor ef-
fect of ET-1 on efferent arterioles. The inconsistent observations re-
garding the constrictor actions of ET-1 in afferent and efferent
arterioles may be explained by different experimental set-up (isolat-
ed arterioles vs. in vivo infusion studies) and species related differ-
ences (mouse, rabbit or humans). An actual consensus would be
that ETA and ETB receptors on cortical afferent arterioles have constrictor
effects whereas ETB receptors on efferent arterioles are rather dilator.
In a rat model of renovascular hypertension in which the renal artery
of one kidney is clipped in order to decrease blood supply to the kidney,
chronic ETA receptor blockade increases ischemia-induced ﬁbrosis in the
clipped kidney. In this particular case, ETA receptor blockade – like
angiotensin-converting-enzyme inhibition – may further reduce perfu-
sion pressure, which leads to more severe ischemia (Hocher et al.,
2000). However, ET-1 generally tends to reduce renal blood ﬂowmainly
through the ETA receptor (Evans et al., 2001; Denton et al., 2004).
ETB receptors on EC counter the effect of ETA receptors and partic-
ipate in tonic vasodilation via activation of eNOS and release of pros-
taglandins (Matsuura et al., 1997). However, ETB receptor antagonists
have little effect on renal blood ﬂow and GFR in rodents and humans
(Evans et al., 2001; Dhaun et al., 2007).
Unlike in the cortical nephrons, ETB receptors on both afferent and
efferent arterioles of perfused juxtamedullary nephrons mediate con-
striction under normal conditions (Inscho et al., 2005). In the same in
vitro system, a high salt diet increases ETB receptor expression and
ETB receptors mediate then vasodilation in afferent arterioles
(Schneider et al., 2007).
Renal infusion of ET-1 which reduces cortical blood ﬂow has no effect
on medullary blood ﬂow, even though juxtamedullary arterioles diame-
ter is reduced. A reason for this is the smaller impact of ET-1 on the resis-
tance of juxtamedullary vessels compared to cortical arterioles, in regard
to their bigger resting diameter. Moreover, juxtamedullary arterioles
may affect medullary blood ﬂow only marginally (Denton et al., 2004).
The vasa recta are branches of efferent arterioles which perfuse the
renal medulla. Regulation of vasa recta contraction plays therefore a
major role in medullary blood ﬂow, water and sodium retention. In the
vasa recta, ETB receptors are expressed on EC and ETA receptors on the
Fig. 3. The endothelin system in the glomerulus and possible intercellular actions of ET-1.
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isolated vasa recta mostly through an ETA receptor pathway (Pallone and
Silldorff, 2001). This occurs through the depolarization of pericytes con-
secutive to inhibition of potassium channels. ET-1 could in this way re-
duce renal medullary blood ﬂow (Cao et al., 2005). Nevertheless, after
intravenous injection in rats, ET-1-induced production of NO and prosta-
glandin dilates the vasa recta and thereby elevates medullary blood ﬂow
(Rubinstein et al., 1995). This observation is conﬁrmed by the fact that
ETB receptor blockade prevent ET-1-induced elevation of medullary
blood ﬂow (Evans et al., 2001).
In conclusion, ET-1/ETA contributes to constriction of glomerular
arterioles and reduces renal and cortical blood ﬂow. ET-1 tends to en-
hance medullary blood ﬂow mainly through the ETB receptor, which
participates in tonic renal vascular dilatation.
ET-1 in the tubular system
ET-1 controls channels activity and inhibits salt reabsorption
Proximal tubule. In the rat proximal tubule, ETB receptors, but not ETA,
are expressed and it modulates sodium excretion. ET-1 facilitates na-
triuresis, by inhibiting the Na+/K+-ATPase after activation of ETB re-
ceptors and consequent enhancement of Ca2+ recruitment (Liu et
al., 2009). On the other hand, ETB receptors in the proximal tubule in-
crease the activity of the Na+/H+ exchanger 3 (Laghmani et al., 2001)
and Na+-citrate cotransporter (Liu et al., 2010) which may counter-
acts the effect toward the Na+/K+-ATPase. This phenomenon seems
particularly relevant in the context of acidosis, during which ET-1 ex-
pression by the proximal tubule is enhanced.
Henle's loop. ET-1 expression is relatively low in the thin limb seg-
ments of Henle's loop (Moridaira et al., 2003). In ascending and de-
scending thin limbs, the expression of ETA and ETB receptors is
disputed depending on the species. The presence of a functional
ETA-induced Ca2+ signaling, which may be involved in blood pressure
regulation, has been revealed in the rat thin descending limb (Bailey
et al., 2003). In rats, recent immunohistochemical studies showed
however no receptor expression at all in this part of the nephron
(Wendel et al., 2006; Yamamoto et al., 2008).In the medullary thick ascending limb (TAL), ET-1 expression in-
creases with osmolality. The ETB receptor is the only receptor in the
TAL. It inhibits sodium reabsorption through the activation of phos-
phatidylinositol 3-kinase (PI3K), Akt/Protein kinase B (AKT) and
eNOS, and consecutive elevation in NO production which inhibits
the Na+/K+/Cl- cotransporter (Herrera et al., 2009). In the cortical
TAL of rats, the ETB receptor activation elevates Ca2+ concentration
and NO production which participates to the inhibition of chloride
reabsorption (Plato et al., 2000) (Fig. 2).
Collecting duct. The collecting duct (CD) shows the highest density of
ETB receptors and the strongest ET-1 expression compared to other
cell types but expresses low amount of ETA receptors (Moridaira et al.,
2003). Activation of ETB receptors on the epithelial cells of the CD in-
hibits sodium reabsorption (Fig. 2). ET-1 prevents the activation of
the Na+/K+-ATPase in the CD presumably because of an enhanced
ETB-induced cyclooxygenase activity and prostaglandin production
(Zeidel et al., 1989). Secondly, ET-1 regulates the activity of the epithe-
lial sodium channel (ENaC). In the long term, ET-1 inhibits the opening
probability of ENaC by promoting the guanine exchange factor βpix to
bind the 14-3-3 protein. This prevents the binding of the latter with
nedd4-2 protein, which is required for ENaC activation (Pavlov et al.,
2010). In a rapid fashion, ET-1 induces via the ETB receptor a src kinase
dependent MAPK1/2 activation, which may modify directly the phos-
phorylation status of ENaC. This mechanism does not required PLC or
protein kinase C and may rely speciﬁcally on the ETB receptor (Bugaj
et al., 2011). Finally, eNOS and inducible NOS (iNOS) are both involved
in the inhibition of sodium reabsorption mediated by ET-1 (Fig. 2). In
cells from the inner medullary CD, ET-1 enhances the neuronal NOS
(nNOS) activity via the ETB receptor (Stricklett et al., 2006). eNOS and
nNOS activity is reduced in the CD isolated from ETB-KO mice, but ETA
receptors may be able in these mice to promote nNOS expression
(Sullivan et al., 2007). Finally, the activity of both eNOS and nNOS is
lower in CD speciﬁc ET-1 deﬁcient mice and this is accompanied by
sodium retention (Schneider et al., 2008). Taken together, both ETA
and ETB receptors from the CD prevent sodium reabsorption.
Effects of tubular ET-1 on blood pressure; experiments in animal models.
ETB-KO mice develop salt-sensitive hypertension without endothelial
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ciency in EC does not modify blood pressure, on neither normal nor
high salt diet (Bagnall et al., 2006). Interestingly, female ETB-KO rats
are normotensive but the high salt diet-induced elevation of blood pres-
sure is stronger than in males (Taylor et al., 2003). The protective ETB/
eNOS pathway has a stronger effect in females than in males and may
be responsible for this phenotype (Chappell et al., 2003). To note,
renal ETA receptor expression is diminished in ETB-KO mice. This
could result from an enhanced tissue level of ET-1 consecutive to a re-
duced ET-1 clearance by ETB receptors (Schildroth et al., 2011). The gen-
eration of CD speciﬁc deﬁcient mice for ET-1, ETB, ETA and combined
ETA/ETB receptors revealed that CD-ET-1 is necessary for maintaining
normal blood pressure in vivo. Except CD-ETA KO, all strains are hyper-
tensive suggesting that the ETB receptor alone is responsible for BP reg-
ulation. These results conﬁrmed the predominant role of the ETB receptor
in inhibition of sodium reabsorption. Nevertheless, deletion of the ETB re-
ceptor alone leads to a smaller elevation of arterial BP (10 mmHg) com-
pared to CD-ET-1-KO and combined ETA/ETB-KO (20 mmHg) (Ge et al.,
2008). Under high salt diet, blood pressure further increases in CD-ET-1
KO mice and, if rather modestly, in CD-ETB-KO mice too (15 and
5 mmHg higher than under normal diet, respectively), while BP remains
unchanged in WT and CD-ETA-KO mice. In combined CD-ETA/ETB KO
mice, blood pressure reaches the level of CD-ET-1 KO mice after four
days high salt diet (Ge et al., 2008). Using ETB receptor deﬁcient rats,
Nakano et al. revealed that ETA receptors can induce natriuresis indepen-
dently of its hemodynamic effects through the activation of nNOS in CD
(Nakano and Pollock, 2009). See that ETB receptors show a much higher
density compared to ETA receptors in the CD, absence of the latter alone
may not change CD physiology. ETA receptorsmay regulate sodium reab-
sorption at least in the absence of ETB receptors. The question whether
this effect is due to chronic gene deletion remains open.
Because response to high salt diet in CD-ET-1 KO mice is different
than in combined CD-ETA/ETB KO mice, CD-ET-1 may act on adjacent
structure. This is in line with the lower BP observed in single KO com-
pared to CD-ET-1 KOmice under high-salt diet (Ge et al., 2006, 2008).
Hypotensive effect of furosemide in CD-ET-1 KO mice and amiloride
in CD-ET-1 KO mice and ETB-KO rats conﬁrm the role of ET-1/ETB on
the activity of Na+/K+/Cl− cotransporter and ENaC channel, respec-
tively (Gariepy et al., 2000; Ahn et al., 2004).
In conclusion, ETB and probably ETA receptors as well are respon-
sible for braking salt reabsorption.
ET-1 antagonizes vasopressin actions and regulates blood volume
ET-1 controls water handling in the CD, but not in the TAL. In perfused
CD, it was ﬁrst demonstrated that the vasopressin (AVP)-induced eleva-
tion ofwater permeabilitywas inhibited by ET-1. ET-1 reduces cAMP con-
centration, independently of prostaglandin but dependent on PKC; this
effect is speciﬁc to ETB activation (Kohan et al., 1993). Using the AC-
cAMP-PKApathway, activation of vasopressin receptor 2 (V2R) phosphor-
ylates ETB receptors and provokes its internalization. In a long term, the
same pathway can reduce ETB expression (Wong et al., 2000) while ET-
1/ETB interaction increases V2R expression (Wang et al., 2007). Further-
more, both aquaporin (AQP2) and V2R receptor expression is reduced
by bosentan treatment (Wong et al., 2003).
CD-ET-1 KO mice have an impaired ability to manage an acute
water load. In these mice, the authors observed an elevated AVP-
induced cAMP accumulation, which further proposes that ET-1 de-
creases AVP-induced adenylate cyclase (AC) activity (Ge et al.,
2005a). Abundance of AC itself is enhanced in the CD of CD-ET-1 KO
mice showing that CD-ET-1 exerts a diuretic effect by tonic repression
of AC expression (Strait et al., 2007). Contrarily, CD-ETA KO reduces
sensitiveness to AVP associated and AVP-induced cAMP accumula-
tion, and increases diuresis after an acute water load. ETA receptors
seem to oppose the effects of ETB receptors (Ge et al., 2005b). These
data suggest that ETA receptors could moderate ET-1 predominant
diuretic action, at least after hyperhydration. Given that ET-1 isoverexpressed in such situation, ETA receptors may compensate ET-
1/ETB-induced water loss. On the other hand, recent unpublished ob-
servations using a selective ETA receptor antagonist and tissue specif-
ic ETA receptor deﬁcient mice suggest a diuretic role for CD-ETA.
In conclusion, activation of ETB receptors inhibits AVP-induced
AQP2 activity. ET-1 thereby facilitates diuresis. ETA receptors may at-
tenuate this effect in stress situation.
ET-1 in proliferative tubular disease
In addition to its role in regulating water and salt reabsorption, ET-1
mayparticipate in the development of tubular diseases through itsmito-
gen and pro-ﬁbrotic properties. The endothelin system is activated in
polycystic kidney disease in animal models and humans (Song et al.,
2009). Moreover, genetic overexpression of ET-1 in mice leads to spon-
taneous development of renal cysts (Hocher et al., 1997). In spite of this,
the speciﬁc blockade of ETA or ETB receptors worsens the symptoms,
while combined blockade had no effect in polycystic mice. In this
model, ETB-activated pathway under ETA receptor blockade increases
tubular cell proliferation, and ETA receptor pathway promotes intersti-
tial inﬂammation and ﬁbrosis after ETB receptor inhibition (Chang
et al., 2007). In rats with inherited renal cystic disease, an ETA receptor
antagonist treatment deteriorates renal condition as well (Hocher
et al., 2003). ET-1-induced ischaemia could account for the deleterious
effect mediated by ETB receptors under ETA receptor blockade
(Kakinuma et al., 2001). This particular effect of ET blockade seems to
be speciﬁc to cystic disease: in a proteinuric model, bosentan prevents
tubulo-interstitial lesion and inﬂammation (Suzuki et al., 2001).
ET-1 in the glomerulus
The endothelin system is present throughout the glomerulus
(Fig. 3) (Moridaira et al., 2003; Wendel et al., 2006) and is involved
in both the normal function and pathophysiology of the glomerular
ﬁltration. Under diabetic conditions, the expression of the receptors
remains stable (Watson et al., 2010) but ET-1 expression is enhanced
in the glomerulus (Benigni et al., 1998). In mesangium (MG), ET-1 in-
duces contraction, proliferation and extracellular matrix accumula-
tion (collagen I, IV and ﬁbronectin). This leads to glomerulosclerosis
and kidney failure. Mice carrying an ET-1 transgene develop sponta-
neously glomerulosclerosis and renal ﬁbrosis (Hocher et al., 1997).
Importantly, the effects of AVP and ANGII on MG proliferation and ex-
tracellular matrix production are in part modulated by ET-1/ETA (Kuo
et al., 2006; Tahara et al., 2008). The signaling pathways involved
have been well documented. Activation of ETA receptors activates
PLC which produces IP3 and DAG. DAG activates PKC which phos-
phorylates non-receptor tyrosine kinase Src and stimulates ras and
thus proliferation (Mishra et al., 2005). IP3 promotes release of Ca2+
from the reticular sarcomere. The tyrosine kinase Pyk2 is thus activat-
ed, mediates ET-1 signaling via p130Cas/BCAR3/rap1 and disturbs MG
structure and function (Rufanova et al., 2009). ET-1 inhibits iNOS ex-
pression through ETA receptors. ETB receptor activation in turn en-
hances NO production (Owada et al., 1994). This effect is Ca2+
dependent which excludes the involvement of iNOS. eNOS is present
in MG under high glucose situation only indicating that nNOS may be
the source of ETB-induced NO (Zhang et al., 2007). ET-1 induces epi-
dermal growth factor receptor (EGFR) transactivation, which stimu-
lates proliferative and proﬁbrotic pathways involving Gαi, β1Pix,
and ERK1/2 (Chahdi and Sorokin, 2010). Additionally, ERk5 may
transactivate EGFR under the control of ET-1 (Dorado et al., 2008).
ET-1 promotes also MG hypertrophy through a pathway implicating
PI3K, AKT, NFAT4 and p8 proteins (Goruppi and Kyriakis, 2004).
Podocytes represent the last layer of the glomerular ﬁltration barrier
and their cytoskeleton structure resembling foot process is essential for
correct function. ET-1 destabilizes f-actin ﬁlaments in these cells and
promotes nephrin shedding, which causes foot process effacement,
podocytes detachment and ultimately proteinuria and glomerular
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disassembly in podocytes and elevates ET-1 production, which, in
turn, further destabilizes cytoskeleton arrangement of podocytes. The
podocyte monolayer loses thereby its permeability and proteinuria de-
velops (Morigi et al., 2005). In isolated glomeruli and in rats, an ETA re-
ceptor blockade can reduce albuminuria caused by an ET-1 infusion or
hyperglycemia, independently of vasoconstriction (Saleh et al., 2010,
2011). The decrease of podocyte number induced by diabetes can be
prevented by an ETA receptor blockade in rats (Gagliardini et al.,
2009). Notably, these mechanisms may be induced by angiotensin but
angiotensin-converting enzyme inhibition and ETA receptor blockade
show additive protective effects, indicating ET-1 speciﬁc effects
(Gagliardini et al., 2009). Changes in the structure of the podocytes
caused by puromycin aminonucleoside, an in vitro model for podocyte
damage, are prevented by blocking ETA receptor (but not ETB) in cul-
tured podocytes. In agreement with this, a regression of glomerulo-
sclerosis accompanied by better podocyte function can be observed
after a chronic treatment with darusentan, an ETA antagonist, in aging
rats (Ortmann et al., 2004). The reduction in proteinuria by ETA receptor
antagonism is accompanied by changes of the glomerular basement
membrane composition in experimental diabetes (Hocher et al., 2001).
The presence of ETB receptors on the foot processes suggests a role in ﬁl-
tration (Yamamoto et al., 2002). In diabetic mice, the genetic deletion of
ETB receptors worsens glomerulosclerosis and albuminuria. In this
model, ETB receptor deﬁciency elevates ET-1 serum levels, which induce
a strong hypertension under diabetic condition (Pfab et al., 2006).
Within the glomerulus, the paracrine characteristic of ET-1 is cer-
tainly relevant because of the strong intercellular communication
present in this structure (Coppo et al., 2010) (Fig. 3). For instance,
ET-1 produced by glomerular EC may affect the structure of adjacent
podocytes (Collino et al., 2008).
Clinical use of endothelin antagonists in diabetic nephropathy
In light of the aforementioned preclinical results, the use of
endothelin antagonists has been considered for the treatment of kid-
ney diseases, and particularly diabetic nephropathy. The largest phase
III clinical trial to date testing an endothelin receptor, avosentan 25
and 50 mg/day, conﬁrmed the anti-proteinuric potential of endothelin
antagonists in diabetic nephropathy. However, this study has been
stopped because treated patients developed ﬂuid retention leading to
heart failure (Mann et al., 2010). The selectivity of avosentan has
been put into question earlier (Battistini et al., 2006). A recent study in-
dicates that blocking speciﬁcally ETA receptors reduces proteinuria in
chronic kidney disease patients receiving already an optimal treatment.
On a short term (six weeks), these improvements were not accompa-
nied by adverse side effects (Dhaun et al., 2011). Moreover, lower
dose of avosentan (5–10 mg/day) may be sufﬁcient to prevent albu-
minuria with a limited occurrence of ﬂuid retention compared to
higher dose (Wenzel et al., 2009). Finally, the use of diuretics should
be permitted in the protocol of future clinical studies (Kohan et al.,
2011). Another option to overcome the adverse side effects of endothe-
lin antagonists due to their tubular effects might be endothelin-
converting-enzyme/neutral endopeptidase inhibitors. These drugs are
effective in reducing diabetes-induced kidney damage in rats (Thöne-
Reineke et al., 2004). The increased ANP serum level and the consecu-
tive elevated sodium excretion may counteract the tubular effects of
pure endothelin receptor blockade. The prevention of organ damage
is similar to the one provoked by angiotensin blockade, but presents
the advantage to be blood pressure independent (Kalk et al., 2011).
Conclusion
ET-1 is a multifunctional hormone with complex effects on the renal,
cardiac and vascular physiology. ET-1 is a strong vasoconstrictor while
the activation of the endothelial ETB receptor induces the production ofvasodilator NO. ET-1 has positive inotropic feature but has been shown
to reduce contractility in disease state. ET-1 is overexpressed in the fail-
ing heart but may prevent apoptosis and restore cardiac function in
stress situation. In the kidney, ET-1 is a diuretic and natriuretic hormone
in which it antagonizes its vascular effect on blood pressure. The accu-
mulating research in the endothelin ﬁeld reveals further the complexity
of this system but provides knowledge, whichwill most probably end up
in the development of novel therapies.
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